Expertise in
3
conditions

Dr. Janet Dubois

Dermatology
Ladera Park Dermatology PA
11671 Jollyville Rd Ste 104, 
Austin, TX 
Referral may be required
Expertise in
3
conditions
Ladera Park Dermatology PA
11671 Jollyville Rd Ste 104, 
Austin, TX 

Overview

Janet Dubois is a Dermatologist practicing medicine in Austin, Texas.

Dr. Dubois is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Seborrheic Keratosis, Actinic Keratosis, Rosacea, and Acne.

She is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 10 clinical trials.

Specialties

Dermatology

Licenses

Dermatology in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Ladera Park Dermatology PA
11671 Jollyville Rd Ste 104, Austin, TX 78759
Other Locations
Office
8140 N Mopac Expy Ste 3-120, Austin, TX 78759

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drug: QTORIN rapamycin anhydrous gel
Study Phase: Phase 3
A Randomized, Observer-Blinded, Within Patient Bilateral Comparison to Study the Safety and Efficacy of Daily Application for 4 Weeks of DBI-001 Gel Versus Aqueous Gel in Subjects With Atopic Dermatitis
A Randomized, Observer-Blinded, Within Patient Bilateral Comparison to Study the Safety and Efficacy of Daily Application for 4 Weeks of DBI-001 Gel Versus Aqueous Gel in Subjects With Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2023
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: August 09, 2022
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Phase 2 Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
A Phase 2 Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
Enrollment Status: Completed
Publish Date: July 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
Enrollment Status: Terminated
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b, Multicenter, Open-Label, Parallel-Group, Maximal Use Systemic Exposure (MUSE) Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 Compared to Retin-A® 0.1% in Subjects With Moderate to Severe Acne Vulgaris
A Phase 1b, Multicenter, Open-Label, Parallel-Group, Maximal Use Systemic Exposure (MUSE) Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 Compared to Retin-A® 0.1% in Subjects With Moderate to Severe Acne Vulgaris
Enrollment Status: Completed
Publish Date: March 18, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis
A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Double-Blind, Multi-Center, Randomized, Placebo Controlled Safety, Tolerability & Efficacy Trial Of A New Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment Of Mild-To-Moderate Plaque Psoriasis In Adults
A Double-Blind, Multi-Center, Randomized, Placebo Controlled Safety, Tolerability & Efficacy Trial Of A New Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment Of Mild-To-Moderate Plaque Psoriasis In Adults
Enrollment Status: Completed
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Phase 2
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Enrollment Status: Withdrawn
Publish Date: November 07, 2017
Intervention Type: Drug, Device
Study Phase: Phase 3
View 9 Less Clinical Trials

27 Total Publications

NivobotulinumtoxinA in the Treatment of Lateral Canthal Lines Alone and With Concurrent Treatment of Glabellar Lines.
NivobotulinumtoxinA in the Treatment of Lateral Canthal Lines Alone and With Concurrent Treatment of Glabellar Lines.
Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Published: September 09, 2025
Similar Doctors
Expertise in
79
conditions
Dr. Daniel Taheri
Dermatology
Expertise in
79
conditions
Dr. Daniel Taheri
Dermatology
401 Ranch Road 620 S # 200, 
Lakeway, TX 
 (12.2 miles away)
760-873-8718
Languages Spoken:
English
See accepted insurances

Daniel Taheri is a Dermatologist practicing medicine in Lakeway, Texas. Dr. Taheri is highly rated in 79 conditions, according to our data. His clinical expertise encompasses Comedones, Melanoma, Giant Congenital Melanocytic Nevus, and Familial Atypical Multiple Mole Melanoma Syndrome. Dr. Taheri is board certified in American Board Of Dermatology.

Expertise in
56
conditions
Dr. Stacia Miles
Dermatology
Expertise in
56
conditions
Dr. Stacia Miles
Dermatology
1250 S Capital Of Texas Hwy Fl 1, 
West Lake Hills, TX 
 (10.5 miles away)
512-334-2401
Languages Spoken:
English
See accepted insurances

Stacia Miles is a Dermatologist practicing medicine in West Lake Hills, Texas. Dr. Miles is highly rated in 56 conditions, according to our data. Her clinical expertise encompasses Pustules, Syringocystadenoma Papilliferum, Sebaceous Adenoma, and Syringoma.

Expertise in
34
conditions
Dr. Alicia Miller
Dermatology
Expertise in
34
conditions
Dr. Alicia Miller
Dermatology
425 University Blvd, 
Round Rock, TX 
 (10.6 miles away)
512-509-0200
Languages Spoken:
English
See accepted insurances

Dr. Miller has been recognized as a Top Doc 2020, 2021, 2022, 2023, 2024, and 2025 by Austin Monthly Magazine. Winners are nominated by their peers as among the best in their region/nation in their medical specialty. Dr. Miller is highly rated in 34 conditions, according to our data. Her clinical expertise encompasses Graham-Little-Piccardi-Lassueur Syndrome, Actinic Keratosis, Psoriasis, and Warts. Dr. Miller is board certified in Dermatology- American Board Of Dermatology.

Frequently Asked Questions about Dr. Janet Dubois

How do I make an appointment with Dr. Janet Dubois?

You can book an appointment with Dr. Janet Dubois by calling their office at 512-345-3599. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Janet Dubois a top-rated expert for Seborrheic Keratosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Janet Dubois is classified as an Advanced expert for Seborrheic Keratosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Janet Dubois specialize in?

While Dr. Janet Dubois is a Dermatology, they have specific expertise in Seborrheic Keratosis, Actinic Keratosis, and Rosacea. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Janet Dubois participate in research or clinical trials?

Yes. Dr. Janet Dubois has published 27 articles and abstracts on conditions like Seborrheic Keratosis. You can view a list of Dr. Janet Dubois's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Janet Dubois accept my insurance?

Dr. Janet Dubois accepts most major insurance plans, including Aetna and UnitedHealthcare. We recommend calling the office directly at 512-345-3599 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dubois's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile